Demonstrates efficacy of navepegritide for achondroplasia treatment, suggesting improved patient outcomes.
Navepegritide (Yuviwel), a C-type natriuretic peptide analog, is the second drug to be approved for the treatment of achondroplasia. It is administered subcutaneously once weekly. The retail cost for navepegritide is expected to be almost half a million dollars annually.
No takes yet. Share an insight, caveat, or question.
Diane S. Aschenbrenner (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: